{"filings":[{"id":94608,"accession_number":"0001213900-26-041006","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband selects brand name for abuse-deterrent fentanyl patch; will submit to FDA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selected commercial worldwide brand name candidate for lead product, a fentanyl transdermal system with abuse-deterrent technology.","Will submit proposed brand name and labeling to FDA and international regulators for review and approval; also filing for trademark registration.","Engaged Brand Institute, global leader with 75% share of drug name approvals and 87% of FDA-approved names in 2024.","Product uses AVERSA abuse-deterrent technology; potential peak annual US sales of $80-200 million per market report.","Brand Institute's regulatory subsidiary DSI, led by former FDA/EMA officials, will provide regulatory support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107117,"accession_number":"0001213900-26-016550","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband terminates sale of Pocono Pharmaceuticals to Earth Vision Bio due to buyer default","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved immediate termination of Pocono Pharmaceuticals sale to Earth Vision Bio Inc.","Purchaser failed to close by December 31, 2025 and did not pay applicable late fees.","Nutriband received $30,000 in late fees but no further payments since January 21, 2026.","Company will retain ownership of Pocono Pharmaceuticals after terminated agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107116,"accession_number":"0001213900-26-011304","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Nutriband shareholders approve preferred share increase from 10M to 20M; two new directors appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized preferred shares from 10,000,000 to 20,000,000 with 86.25% of votes cast in favor.","All seven director nominees elected; Gareth Sheridan received 87.96% of shares voted.","Ratification of Sadler, Gibb & Associates as independent auditor for 2025 passed with 87.59% of votes.","Non-binding say-on-pay and say-on-frequency proposals approved (87.78% and 87.16% respectively).","Board appointed Alessandro Puddu (Italian accountant) and Viorica Carlig (aircraft services manager) as new directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123454,"accession_number":"0001213900-25-126650","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband sells 90% stake in Pocono Pharma for $5M to EarthVision Bio; retains 10%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Agreement to sell 90% interest in subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio.","Nutriband shareholders will retain 10% stake in EarthVision Bio post-acquisition; closing expected Dec 31, 2025.","Proceeds will fund continued development of AVERSA Fentanyl, an abuse-deterrent opioid patch.","AVERSA Fentanyl has potential annual US sales estimate of $80M to $200M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123453,"accession_number":"0001213900-25-102930","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband receives FDA feedback on AVERSA FENTANYL CMC plans; regulatory pathway confirmed as 505(b)(2)","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA meeting held September 18, 2025; final minutes received; feedback on CMC, registration batch, and stability plans.","FDA confirmed 505(b)(2) NDA path and provided guidance on reference drug bridging strategy.","Company plans to file IND to support a Human Abuse Potential clinical study for the abuse-deterrent fentanyl patch.","Partner Kindeva to develop AVERSA FENTANYL combining Nutriband's AVERSA technology with Kindeva's FDA-approved fentanyl patch.","Peak annual US sales potential estimated at $80M to $200M per market analysis report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140127,"accession_number":"0001213900-25-083882","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband discloses option/warrant exercises from Feb-Jul 2025 totaling 845K shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock options exercised on 20,055 shares for $44,206 total exercise price.","Public warrants (NTRBW) exercised on 47,076 shares for $302,699.","Private investor warrants exercised on 778,041 shares for $5,002,804.","Total shares from exercises: 845,172; disclosure voluntary under Item 7.01."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140126,"accession_number":"0001213900-25-073116","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["3.02","5.03","9.01"],"status":"ready","headline":"Nutriband issues Series A Preferred stock dividend of 3,008,643 shares to common holders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock dividend of Series A Preferred Stock: 1 share for every 4 common shares, issued Aug 5, 2025.","Total of 3,008,643 Series A Preferred shares issued based on July 25, 2025 record date.","Series A Preferred is non-voting; converts to common stock upon FDA approval of AVERSA technology.","Board authorized up to 10,000,000 shares; initially 2,788,678 then increased by correction.","Shares are restricted and held by transfer agent; not transferable until SEC registration and Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140125,"accession_number":"0001213900-25-064355","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Nutriband declares Series A Convertible Preferred stock dividend; record date July 25, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board authorized 2,788,678 shares of Series A Convertible Preferred Stock (non-voting).","Dividend of one Series A Preferred share for every four common shares owned.","Record date: July 25, 2025; conversion to common only after FDA approval of AVERSA transdermal products.","Series A Preferred shares eligible for dividends declared on common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157769,"accession_number":"0001213900-25-030175","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband signs Associate Partnership with MLS team Charlotte FC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Charlotte FC (Major League Soccer) to build brand visibility.","Focus on AI Tape, manufactured locally at Pocono facility in North Carolina.","Also intends to promote AVERSA abuse-deterrent patch technology.","No financial terms disclosed; partnership is marketing-focused."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176142,"accession_number":"0001213900-25-013266","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband formalizes exclusive Aversa Fentanyl partnership with Kindeva; potential $80-200M US sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Signed addendum formalizing exclusive development partnership for Aversa Fentanyl with Kindeva Drug Delivery.","Partnership based on shared development costs in exchange for milestone payments.","Aversa Fentanyl combines Nutriband's abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch.","Estimated peak annual US sales potential of $80M to $200M.","AVERSA technology protected by patents in 46 countries including US, Europe, Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176141,"accession_number":"0001213900-25-012896","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband receives USPTO Notice of Allowance for Aversa abuse deterrent patent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notice of Allowance received Feb 3, 2025 for patent app 18/369,241 covering Aversa abuse deterrent transdermal systems.","US patent expected to issue after administrative processes; expands US IP protection for abuse deterrent transdermal portfolio.","Lead product Aversa Fentanyl could become first abuse-deterrent opioid patch; potential peak US sales $80-200M per Health Advances.","Aversa technology already protected by patents in 46 countries including US, Europe, Japan, China, Canada, Mexico, Australia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176140,"accession_number":"0001213900-25-007938","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nutriband stockholders elect directors, approve auditor and stock plan at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with ~99% of votes cast; each received over 7.4M for votes.","Ratification of Sadler, Gibb & Associates as auditor approved: 7,383,020 for, 65,113 against.","2024 Amended and Restated Stock Option Plan approved: 7,262,469 for, 185,664 against.","Say-on-pay advisory vote passed: 7,420,065 for, 28,068 against; frequency set to 1 year.","Approximately 67.1% of outstanding shares voted (7,448,133 of 11,106,185)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193049,"accession_number":"0001213900-24-113463","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband extends AVERSA patent to Macao; now covered in 46 countries","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Macao IP Office assigned patent number J/9010 with entry date December 17, 2024.","AVERSA abuse-deterrent technology now patented in 46 countries and territories.","Company targets FDA submission for AVERSA Fentanyl in first half of 2025.","AVERSA Fentanyl has potential peak US sales of $80M to $200M per Health Advances report.","Partnership with Kindeva Drug Delivery for lead product using FDA-approved fentanyl patch system."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193048,"accession_number":"0001213900-24-092676","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband receives Chinese patent for AVERSA abuse-deterrent transdermal system","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CNIPA fully issued Patent No. ZL 202211158031 for 'Abuse and Misuse Deterrent Transdermal System' related to AVERSA technology.","Patent covers taste aversion to prevent abuse of opioid patches; previously allowed in September 2024.","AVERSA IP portfolio now includes granted patents in US, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China.","Lead product under development is an abuse-deterrent fentanyl patch incorporating AVERSA technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209416,"accession_number":"0001213900-24-079788","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband announces $1 million share repurchase program; reaffirms AVERSA Fentanyl NDA timeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share buyback program authorizes repurchase of up to $1,000,000 of common stock.","Company had 11,106,185 shares outstanding as of September 16, 2024.","Maintains target to submit AVERSA Fentanyl NDA to FDA in Q1/Q2 2025.","Repurchase program effective immediately; no expiration date disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227431,"accession_number":"0001213900-24-049007","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K/A","filed_at":"2024-06-03T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Nutriband amends 8-K to disclose warrants omitted from prior conversion filing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment adds 152,460 warrants to purchase common stock at $6.43 per share, expiring May 14, 2029.","Warrants were issued to TII Jet Services LDA alongside 76,230 shares at $4.00 conversion of $300K debt.","Original 8-K filed May 21, 2024 omitted the warrant description; corrected via Amendment No. 1.","Conversion and warrant issuance are unregistered sales of equity securities pursuant to Item 3.02.","Exhibit 10.34 contains the May 22, 2024 Amendment to Note Conversion Agreement detailing the modification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227434,"accession_number":"0001213900-24-045330","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Nutriband converts $300K debt into 76,230 shares at $4.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Converted $300,000 principal plus $4,921.79 accrued interest on a Creditline Promissory Note.","Conversion price of $4.00 per share; 76,230 shares of common stock issued to TII Jet Services LDA.","Effective May 14, 2024; shares issued as unregistered securities under an exemption.","Reduces outstanding note debt while increasing share count and diluting existing holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227433,"accession_number":"0001213900-24-044425","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nutriband appoints Sergei Glinka as director effective May 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Sergei Glinka as a director effective May 15, 2024.","Glinka, 58, has been Commercial Manager at TG Biochemicals Limited (Cyprus) since 2019.","He has also served on the board of GST Investments OÜ (Estonia) since 2019.","He graduated from Tallinn Merchant Marine School in 1986."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227432,"accession_number":"0001213900-24-035276","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nutriband raises $8.4M in Regulation S equity offering of units with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 2.1M units at $4.00 each, each unit comprising one common share and warrant to buy two shares.","Warrants exercisable at $6.43 per share, cash only, expiring April 19, 2029.","Total gross proceeds of $8.4M from European investors under Regulation S exemption.","Warrants exercisable immediately; no registration statement for shares or warrants.","Proceeds to be used for general corporate purposes (not specified)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246302,"accession_number":"0001213900-24-027338","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Nutriband grants stock options to CEO, President, CFO, COO, CSO and amends stock plan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Item 3.02: Unregistered sales of options to purchase 97,500 shares each to CEO Gareth Sheridan and President Serguei Melnik at $2.61/share.","Options also granted to CFO Gerald Goodman (75,000 shares), COO Alan Smith (70,000), CSO Jeff Patrick (25,000), and others at $2.37/share.","Item 8.01: Board adopted amendment to 2021 Employee Stock Option Plan, increasing shares from 875,000 to 1,400,000.","Amendment to be submitted to stockholders at 2025 Annual Meeting; if not approved within one year, void and options issued pending approval null.","Item 3.02 also includes a warrant to purchase 15,000 shares to counsel Michael Paige at $2.37/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246301,"accession_number":"0001213900-24-006496","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nutriband stockholders elect six directors, ratify auditor, approve say on pay, choose 1-year frequency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected: Sheridan, Melnik, Hamilton, Bujoreanu, Mancas, Gram each with >5.2M votes for.","Ratification of Sadler, Gibb & Associates as auditor: 5,720,198 for, 27,097 withheld, 56 against.","Advisory say on pay approved: 5,299,717 for, 46,012 withheld, 637 against, 400,985 abstain.","Frequency of say on pay set at 1 year: 5,319,922 votes for 1 year, 18K for 3 years, 1,334 for 2 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246300,"accession_number":"0001213900-24-003023","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband signs commercial development & clinical supply agreement with Kindeva for Aversa Fentanyl patch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kindeva to perform commercial process development & supply clinical materials for FDA abuse liability study.","Agreement replaces prior feasibility deal; moves AVERSA Fentanyl toward NDA filing.","AVERSA Fentanyl estimated peak annual US sales $80M-$200M per Health Advances 2022 market analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263739,"accession_number":"0001213900-23-100093","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Nutriband converts $2M note into 1.03M shares at $2.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder TII Jet Services LDA converted $2M principal plus $53,440 accrued interest into 1,026,720 common shares at $2.00/share.","Conversion reduces outstanding debt by $2M and increases common shares outstanding by about 1.03 million.","Shares issued under an exemption from registration; no underwriter involved.","The converted note was originally dated July 13, 2023, with a maturity of July 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}